Abcam to Open Office in Shanghai, China to Support Chinese Customers
Abcam plc, a global leader in the supply of innovative protein research tools, will open a new office in February 2014, in Shanghai, China. The new hub is the company’s ninth global office, and has been established to support Abcam’s focus on increasing geographic reach and improving distribution channels to rapidly growing markets.
Located in Zhangjiang Hi-Tech Park, Pudong New District, a prominent economic growth and innovation area, the office is within close proximity of the City and Abcam’s production facility in Hangzhou, which develops pioneering research tools such as RabMAb®, its proprietary rabbit monoclonal antibody technology.
The office will house customer and technical support functions, provided by native Mandarin speakers, as well as a product warehouse, which will facilitate local stock storage for the first time. This means that customers will benefit from improved delivery times, with the large majority of orders arriving at their door within 24 hours. The proximity of the office will also enable Abcam to support customers with more specific needs through its extensive range of products and services, including custom antibody production.
Dr Jonathan Milner, CEO, Abcam, said: “China is an important market for Abcam and we’re pleased to provide enhanced services such as faster delivery and dedicated local language support to our customers. Further future investments will ensure we continue to deliver innovative products and services to enable scientists to discover more.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.